glp 1 agonist nash Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? Full article: GLP-1 receptor agonists

In the SURMOUNT-1 trial, tirzepatide produced dose-dependent weight reductions, with average losses approaching or exceeding ~20% at higher doses in adults with obesity who did not have diabetes, numbers that markedly exceed historical pharmacotherapy benchmarks

A Western diet is known to increase both glycogen and fat in the liver, and, as expected, both glycogen and liver fat (triglycerides) were markedly elevated in the WD+stevia group (Figure 3AC)

Only your healthcare team can decide which of these drugs, if any, will work best for you

Stay hydrated: Polyphenols work best in well-hydrated tissue

Infusions with GIP(3-30)NH 2 in healthy individuals during a mixed meal test or an oral glucose tolerance test as well as in persons with obesity in the fasting state do not affect glucagon levels (87, 90)